Conditions – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Thu, 19 Oct 2023 00:33:09 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Conditions – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 Clinical, Cognitive, and Neurobiological Correlates of Impaired Timing Abilities Associate to Cannabis Use: a Systematic Review https://www.cannabisclinicians.org/2023/10/18/clinical-cognitive-and-neurobiological-correlates-of-impaired-timing-abilities-associate-to-cannabis-use-a-systematic-review/ Thu, 19 Oct 2023 00:33:09 +0000 https://www.cannabisclinicians.org/?p=29471 Time perception received growing interest in psychiatry for its psychopathological implications. Cannabis use can cause a subjective experience of temporal perception alteration and increases the risk of emergence of mental illnesses such as psychotic and mood disorders. In this framework, we systematically reviewed the findings regarding the clinical, cognitive, and neurobiological correlates of time alterations due to cannabis consumption. According to preclinical results, cannabis exerts a dose-dependent time overestimation, associated with motor inhibition and circadian alterations. Clinical results reported that cannabis impair time estimation and time reproduction abilities, causing subjective temporal fragmentation and depersonalization symptoms. The alteration of timing mediated by cannabis use might depend on a dopaminergic indirect action and on structural, functional, and metabolic alterations of the cerebello-thalamo-cortical circuit. Despite the potential interest, however, only few studies explored the link between cannabis-induced alterations of time processing and psychiatric symptoms.

The post Clinical, Cognitive, and Neurobiological Correlates of Impaired Timing Abilities Associate to Cannabis Use: a Systematic Review appeared first on Society of Cannabis Clinicians.

]]> Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy https://www.cannabisclinicians.org/2023/10/18/updated-clinical-recommendations-for-the-management-of-tuberous-sclerosis-complex-associated-epilepsy/ Thu, 19 Oct 2023 00:26:27 +0000 https://www.cannabisclinicians.org/?p=29468 Children with tuberous sclerosis complex (TSC), may experience a variety of seizure types in the first year of life, most often focal seizure sand epileptic spasms. Drug resistance is seen early in many patients, and the management of TSC associated epilepsy remain a major challenge for clinicians. In 2018 clinical recommendations for the management of TSC associated epilepsy were published by a panel of European experts. In the last five years considerable progress has been made in understanding the neurobiology of epileptogenesis and three interventional randomized controlled trials have changed the therapeutic approach for the management of TSC associated epilepsy. Pre-symptomatic treatment with vigabatrin may delay seizure onset, may reduce seizure severity and reduce the risk of epileptic encephalopathy.

The post Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy appeared first on Society of Cannabis Clinicians.

]]> Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review https://www.cannabisclinicians.org/2023/10/18/emerging-therapeutic-potential-of-cannabidiol-cbd-in-neurological-disorders-a-comprehensive-review/ Wed, 18 Oct 2023 23:54:48 +0000 https://www.cannabisclinicians.org/?p=29460 Δ9-Tetrahydrocannabinol (Δ9-THC) is a principal psychoactive extract of Cannabis sativa and has been traditionally used as palliative medicine for neuropathic pain. Cannabidiol (CBD), an extract of hemp species, has recently attracted increased attention as a cancer treatment, but Δ9-THC is also requiring explored pharmacological application. This study evaluated the pharmacological effects of Δ9-THC in two human colorectal cancer cell lines. We inves-tigated whether Δ9-THC treatment induces cell death in human colorectal cancer cells.

The post Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review appeared first on Society of Cannabis Clinicians.

]]> Cell death induction and intracellular vesicle formation in human colorectal cancer cells treated with Δ9 -Tetrahydrocannabinol https://www.cannabisclinicians.org/2023/10/18/cell-death-induction-and-intracellular-vesicle-formation-in-human-colorectal-cancer-cells-treated-with-%ce%b49-tetrahydrocannabinol/ Wed, 18 Oct 2023 11:22:50 +0000 https://www.cannabisclinicians.org/?p=29453 Δ9-Tetrahydrocannabinol (Δ9-THC) is a principal psychoactive extract of Cannabis sativa and has been traditionally used as palliative medicine for neuropathic pain. Cannabidiol (CBD), an extract of hemp species, has recently attracted increased attention as a cancer treatment, but Δ9-THC is also requiring explored pharmacological application. This study evaluated the pharmacological effects of Δ9-THC in two human colorectal cancer cell lines. We inves-tigated whether Δ9-THC treatment induces cell death in human colorectal cancer cells.

The post Cell death induction and intracellular vesicle formation in human colorectal cancer cells treated with Δ9 -Tetrahydrocannabinol appeared first on Society of Cannabis Clinicians.

]]> A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality https://www.cannabisclinicians.org/2023/10/16/a-double-blind-randomized-placebo-controlled-study-of-the-safety-and-effects-of-cbn-with-and-without-cbd-on-sleep-quality/ Mon, 16 Oct 2023 12:00:00 +0000 https://www.cannabisclinicians.org/?p=29444 The present study sought to determine the effects of cannabinol (CBN) alone and in combination with cannabidiol (CBD) on sleep quality. This was a double-blind, randomized, placebo-controlled study conducted between May and November 2022. Participants were randomized to receive either (a) placebo, (b) 20 mg CBN, (c) 20 mg CBN + 10 mg CBD, (d) 20 mg CBN + 20 mg CBD, or (e) 20 mg CBN + 100 mg CBD for seven consecutive nights. Participants were 18–55 years of age who self-rated sleep quality as “very poor” or “poor.” The primary endpoint was sleep quality, while secondary endpoints included sleep onset latency, number of awakenings, wake after sleep onset (WASO), overall sleep disturbance, and daytime fatigue

The post A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality appeared first on Society of Cannabis Clinicians.

]]> Anxiety severity and prescription medication utilization in first-time medical marijuana users https://www.cannabisclinicians.org/2023/10/14/anxiety-severity-and-prescription-medication-utilization-in-first-time-medical-marijuana-users/ Sun, 15 Oct 2023 02:34:43 +0000 https://www.cannabisclinicians.org/?p=29435 Anxiety and post-traumatic stress disorder (PTSD) are qualifying psychiatric conditions for medical marijuana (MM) treatment in Pennsylvania. This study examined baseline prevalence and changes in prescription anxiety medication use three months following MM treatment initiation among individuals with these qualifying conditions. The study sample was comprised of 108 adults with anxiety or PTSD as a referring condition; they were enrolled in a longitudinal study evaluating biopsychosocial outcomes in new MM patients. Consenting participants completed an assessment battery at baseline and Month 3 (n = 94, 87 % follow-up rate) that included a measure of anxiety severity and questions about current anxiety medication prescription and desired (baseline) and actual (Month 3) reductions in medication use.

The post Anxiety severity and prescription medication utilization in first-time medical marijuana users appeared first on Society of Cannabis Clinicians.

]]> Anti-proliferative effect of Cannabidiol in Prostate cancer cell PC3 is mediated by apoptotic cell death, NFκB activation, increased oxidative stress, and lower reduced glutathione status https://www.cannabisclinicians.org/2023/10/12/anti-proliferative-effect-of-cannabidiol-in-prostate-cancer-cell-pc3-is-mediated-by-apoptotic-cell-death-nf%ce%bab-activation-increased-oxidative-stress-and-lower-reduced-glutathione-status/ Thu, 12 Oct 2023 21:49:38 +0000 https://www.cannabisclinicians.org/?p=29417 Prostate cancer is the second most frequent cancer diagnosed in men in the world today. Almost all prostate cancers are adenocarcinomas and develop from gland cells. We used the PC3 prostate cancer cell line, which is well studied and derived from a bone metastasis of a grade IV prostatic adenocarcinoma. Cannabidiol (CBD), a major non-psychoactive constituent of cannabis, is a cannabinoid with anti-tumor properties but its effects on prostate cancer cells are not studied in detail. Here, we found cannabidiol decreased prostate cancer cell (PC3) viability up to 37.25% and induced apoptotic cell death in a time and dose-dependent manner. We found that CBD activated the caspases 3/7 pathways and increased DNA fragmentation. Furthermore, we observed an increase of pro-apoptotic genes Bax, an increased level of reactive oxygen species, lower reduced glutathione level, and altered mitochondrial potential in response to CBD treatment leading to lower cellular ATP. Overall, our results suggest that CBD may be effective against prostate cancer cells.

The post Anti-proliferative effect of Cannabidiol in Prostate cancer cell PC3 is mediated by apoptotic cell death, NFκB activation, increased oxidative stress, and lower reduced glutathione status appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol attenuates inflammatory impairment of intestinal cells expanding biomaterial-based therapeutic approaches https://www.cannabisclinicians.org/2023/10/09/cannabidiol-attenuates-inflammatory-impairment-of-intestinal-cells-expanding-biomaterial-based-therapeutic-approaches/ Mon, 09 Oct 2023 16:08:11 +0000 https://www.cannabisclinicians.org/?p=29389 Cannabis-based biomaterials have the potential to deliver anti-inflammatory therapeutics specifically to desired cells, tissues, and organs, enhancing drug delivery and the effectiveness of anti-inflammatory treatment while minimizing toxicity. As a major component of Cannabis, Cannabidiol (CBD) has gained major attention in recent years because of its potential therapeutic properties, e.g., for restoring a disturbed barrier resulting from inflammatory conditions. The aim of this study was to test the hypothesis that CBD has beneficial effects under normal and inflammatory conditions in the established non-transformed intestinal epithelial cell model IPEC-J2.

The post Cannabidiol attenuates inflammatory impairment of intestinal cells expanding biomaterial-based therapeutic approaches appeared first on Society of Cannabis Clinicians.

]]> Cannabinoid modulations of pain and stress related circuits https://www.cannabisclinicians.org/2023/10/02/cannabinoid-modulations-of-pain-and-stress-related-circuits/ Mon, 02 Oct 2023 21:41:37 +0000 https://www.cannabisclinicians.org/?p=29344 In the past decade, significant advancements have been made in understanding the brain regions and neuronal circuits regulating neurological behaviors. The endocannabinoid (eCB) system, which is ubiquitously distributed in the brain and extensively involved in synaptic modulation, has been believed to play potential roles in neuronal circuit processes and related disorders. Although eCB-based pharmacological studies have made some clinical achievements, they still often encounter conflicting reports or undesired effects due to global manipulation of manifold brain regions and neuronal circuits, which impede the therapeutic application of eCB-based medications. In this review, we are devoted to discussing the versatile forms of eCB-mediated synaptic plasticity and dissecting currently well-studied specific cannabinoid circuits involved in behavioral domains which are closely linked to the organism’s survival and life quality, such as pain perception and stress-related emotion disorders. By gaining new insights into selective cannabinoid control in circuits, we can potentially mitigate the drawbacks of traditional pharmacology and facilitate the development of precision medicine with novel therapeutic strategies and drug discoveries.

The post Cannabinoid modulations of pain and stress related circuits appeared first on Society of Cannabis Clinicians.

]]> Association between marijuana use and kidney stone: a cross-sectional study of NHANES 2009 to 2018 https://www.cannabisclinicians.org/2023/10/02/association-between-marijuana-use-and-kidney-stone-a-cross-sectional-study-of-nhanes-2009-to-2018/ Mon, 02 Oct 2023 21:20:21 +0000 https://www.cannabisclinicians.org/?p=29336 The purpose of this investigation is to determine whether regular marijuana use is related to history of kidney stones in the US population. Data were obtained from the National Health and Nutrition Examination Survey (NHANES) from 2009 to 2018. Kidney stone and marijuana use data were collected from self-report questionnaires. Multivariate logistic regression and multiple sensitivity analyses were applied to examine the relationship between marijuana usage and kidney stones.

The post Association between marijuana use and kidney stone: a cross-sectional study of NHANES 2009 to 2018 appeared first on Society of Cannabis Clinicians.

]]>